Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PGR | P06401 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360925 | 0.89 | PGR (0.35) | KDM4EALDH1A1PGRCYP2C19MAPK1 | |
| SCHEMBL14390046 | 0.84 | CRHR1 (0.34) | ARCRHR1 | |
| SCHEMBL4354581 | 0.83 | CRHR1 (0.32) | CRHR1 | |
| SCHEMBL4352114 | 0.80 | KDM4E (0.41) | KDM4EALDH1A1PGRCYP2C19MAPK1 | |
| SCHEMBL12094772 | 0.75 | PGR (0.36) | KDM4EALDH1A1PGRCYP2C19MAPK1 | |
| SCHEMBL2395605 | 0.74 | PLK1 (0.39) | KDM4EALDH1A1PGRCYP2C19MAPK1 | |
| SCHEMBL5624907 | 0.73 | SMN1; SMN2 (0.46) | KDM4EALDH1A1CYP2C19MAPK1HSD17B10 | |
| SCHEMBL14390043 | 0.72 | FFAR2 (0.36) | CRHR1 | |
| SCHEMBL4357310 | 0.68 | CETP (0.37) | — | |
| SCHEMBL5624337 | 0.68 | KDM4E (0.44) | KDM4EALDH1A1MAPK1CASP1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622242-B | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG | 2013-07-17 | — | — | CN | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| CN-101622242-A | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG | 2010-01-06 | — | — | CN | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | CETP, LCAT, CES1 | KDM4E 1621/4885ALDH1A1 3563/4885PGR 1740/4885 |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | CETP, LCAT, CES1 | KDM4E 1621/4885ALDH1A1 3563/4885PGR 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.